Evaluation of Paraoxonase, Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical, Atypical and Combined Antipsychotic Treatment

다국어 초록 (Multilingual Abstract)

Objective: Human serum paraoxonase (PON1) prevents lipids from peroxidation and functions as an antioxidant mechanism.
Malonyldialdehyde (MDA) is the final product of lipid peroxidation and can be used as an indicator of oxidative stress. The aim of this study was to investigate PON1, MDA, and arylesterase (ARY) levels in schizophrenic patients who are taking typical, atypical, or combined (typical and atypical) antipsychotic drug treatment, with respect to those of healthy controls.
Methods: We evaluated 41 patients (11 taking typical antipsychotics, 19 taking atypical antipsychotics, 11 taking combined antipsychotics) and 43 healthy controls.
Results: MDA levels were higher in schizophrenic patients taking typical antipsychotics compared with healthy controls (p=0.001).
ARY levels were higher in patients taking atypical antipsychotics compared with healthy controls (p=0.005). PON1 activity was similar in all groups.
Conclusion: Our results indicate that treatment with typical antipsychotic drugs could be related to increased MDA levels; and antipsychotic medication may increase PON1 levels in schizophrenic patients.

참고문헌 (Reference)

1 Ganesan Venkatasubramanian, "Understanding Schizophrenia as a Disorder of Consciousness: Biological Correlates and Translational Implications from Quantum Theory Perspectives" 대한정신약물학회 13 (13): 36-47, 2015

2 Précourt LP, "The three-gene paraoxonase family:physiologic roles, actions and regulation" 214 : 20-36, 2011

3 Akyol O, "The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance" 26 : 995-1005, 2002

4 Eckerson HW, "The human serum paraoxonase/arylesterase polymorphism" 35 : 1126-1138, 1983

5 김성진, "The Relationship between Language Ability and Cognitive Function in Patients with Schizophrenia" 대한정신약물학회 13 (13): 288-295, 2015

6 Scottish Schizophrenia Research Group, "Smoking habits and plasma lipid peroxide and vitamin E levels in never-treated first-episode patients with schizophrenia" 176 : 290-293, 2000

7 Juretić D, "Serum paraoxonase activities in hemodialyzed uremic patients: cohort study" 42 : 146-150, 2001

8 Sasi Neelamekam, "Regulation of Interleukin-6 and Leptin in Schizophrenia Patients: A Preliminary Analysis" 대한정신약물학회 12 (12): 209-214, 2014

9 Unsal C, "Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine" 9 : 1545-1552, 2013

10 Gan KN, "Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities" 19 : 100-106, 1991

11 Park SW, "Protective effects of atypical antipsychotic drugs against MPP(+)-induced oxidative stress in PC12 cells" 69 : 283-290, 2011

12 Noto C, "Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone" 68 : 210-216, 2015

13 Selek S, "Oxidative imbalance in obsessive compulsive disorder patients: a total evaluation of oxidant-antioxidant status" 32 : 487-491, 2008

14 Ganesan Venkatasubramanian, "Neuroimmunological Aberrations and Cerebral Asymmetry Abnormalities in Schizophrenia: Select Perspectives on Pathogenesis" 대한정신약물학회 12 (12): 8-18, 2014

15 Bulut M, "Malondialdehyde levels in adult attentiondeficit hyperactivity disorder" 32 : 435-438, 2007

16 Mehmet Akif Camkurt, "Investigation of Dysregulation of Several MicroRNAs in Peripheral Blood of Schizophrenia Patients" 대한정신약물학회 14 (14): 256-260, 2016

17 Mackness B, "Human serum paraoxonase" 31 : 329-336, 1998

18 Lan-Ting Lee, "Holistic Consideration of Patients with Schizophrenia to Improve Medication Adherence and Outcomes" 대한정신약물학회 13 (13): 138-143, 2015

19 Behl C, "Haloperidolinduced cell death--mechanism and protection with vitamin E in vitro" 7 : 360-364, 1995

20 Herken H, "Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia" 6 : 66-73, 2001

21 Camkurt MA, "Evaluation of malondialdehyde, superoxide dismutase and catalase activity and their diagnostic value in drug naïve, first episode, non-smoker major depression patients and healthy controls" 238 : 81-85, 2016

22 Anupa A. Vijayakumari, "Effect of Polymorphisms of Three Genes Mediating Monoamine Signalling on Brain Morphometry in Schizophrenia and Healthy Subjects" 대한정신약물학회 13 (13): 68-82, 2015

23 Parikh V, "Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain" 37 : 43-51, 2003

24 Güneş M, "Diagnostic performance of increased prolidase activity in schizophrenia" 613 : 36-40, 2016

25 Sarandol A, "Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment" 21 : 857-863, 2007

26 Camkurt MA, "Comparison of plasma MicroRNA levels in drug naive, first episode depressed patients and healthy controls" 69 : 67-71, 2015

27 Kuloglu M, "Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder" 20 : 171-175, 2002

28 Hsu JW, "Association of thalamic serotonin transporter and interleukin-10 in bipolar I disorder: a SPECT study" 16 : 241-248, 2014

29 Grignon S, "Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations" 31 : 365-369, 2007

30 노대영, "Antipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year Comparison" 대한정신약물학회 13 (13): 275-282, 2015

31 Mackness MI, "Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation" 349 : 851-852, 1997

32 Draper HH, "A comparative evaluation of thiobarbituric acid methods for the determination of malondialdehyde in biological materials" 15 : 353-363, 1993